Fiscal Year 2025 Numbers at a Glance
The U.S. Department of Justice (DOJ) released its False Claims Act (FCA) data for fiscal year (FY) 2025, on January 15, 2026. Settlements and judgments in False Claims Act cases totaled over $6.8 billion, the highest number in a single year in the history of the FCA. Whistleblower suits also broke records, with 1,297 new qui tam suits filed in FY 2025, breaking FY 2024’s record of 979.
While we are hopeful that these numbers hold, they do include large judgments that are on appeal and for which the government has not yet recovered any funds, such as the $1.6 billion trial verdict against Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Deputy Assistant Attorney General Brenna Jenny of the DOJ’s Civil Division praised enforcement efforts in the past year:
“The Department’s False Claims Act enforcement is guided by a simple principle: the statute is a powerful tool, and it should be used responsibly. The record-breaking recoveries announced today show our commitment to holding bad actors accountable, safeguarding taxpayer dollars, and protecting vulnerable populations.”
Since its revamp in 1986, the False Claims Act has recovered more than $85 billion in settlements and judgements. In FY 2025, whistleblowers remain a critical tool in the fight against fraud, with over $5.3 billion of the recoveries resulting from qui tam litigation.
Over 83 percent of recoveries this year arose from the healthcare industry, totaling over $5.7 billion. DOJ continued enforcement efforts in managed care, prescription drugs, and medically unnecessary care. DOJ settled several managed care lawsuits, including a $98 million settlement with Independent Health Association and a $62 million settlement with Seoul Medical Group Inc. Pharmaceutical fraud remained an enforcement priority as well, with DOJ settling several cases including a $425 million settlement against the largest generic drug manufacturer, Teva Pharmaceuticals and a $176 million settlement against Gilead Sciences. Most notably, an unanimous jury entered a judgement of $948.8 million against Omnicare.
DOJ continued to devote efforts to recover millions lost to pandemic fraud, including an $8.1 million settlement against Delta Air Lines for Paycheck Protection Program (“PPP”) fraud.
In addition to healthcare and pandemic fraud, DOJ had a renewed focus on customs fraud, launching a cross-agency Trade Fraud Task Force to combat trade fraud. DOJ secured major settlements in customs antidumping cases, including a $54.4 million settlement against Ceratizit USA LLC and a $12.4 million settlement against Stone Inc. and its president.
